Montreal – TheNewswire - August 1, 2023 – Tetra Bio-Pharma Inc. (“ Tetra ” or the “ Company ”) (TSX:TBP) (OTC:TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development announced that it has made a voluntary assignment into bankruptcy under the Bankruptcy and Insolvency Act (Canada) . HOULE ROY S.A. (the “ Trustee ”) has been appointed as Tetra’s trustee in bankruptcy. On March 7, 2023, the corporation... Read More

MONTREAL, QUEBEC – TheNewswire – May 11, 2023 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTC:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, today announced it has cancelled its New Drug Submission (NDS) to Health Canada, without prejudice to a refiling once it has completed a new clinical trial that addresses deficiencies raised by the regulator. The NDS was intended to... Read More

Montreal, QC - TheNewswire - March 10, 2023 - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTC:TBPMF) (FRA:JAM1) , a leader in cannabinoid-derived drug discovery and development is pleased to announce Health Canada has issued the Company a No Objection Letter (NOL) to proceed with its first in human clinical trial using oral ARDS-003 to treat various immunomodulatory conditions, in Canada. Tetra Bio-Pharma... Read More

MONTREAL, QUEBEC – TheNewswire – March 7, 2023 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTC:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announces that further to its press release dated March 1, 2023, the Ontario Securities Commission (OSC) notified the Company that the Company’s application for a management cease trade order (MCTO) has been denied. The OSC has... Read More

The Company is receiving up to $150,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the development of its novel oral therapeutic for systemic hyperinflammation. MONTREAL, QUEBEC – TheNewswire - March 3, 2023 - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTC:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and... Read More

MONTREAL, QUEBEC – TheNewswire – March 1, 2023 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTC-PINK: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that it will not be in a position to file its audited annual financial statements for the year ended November 30, 2022, the related management's discussion and analysis and related CEO and CFO certificates... Read More

MONTREAL , Feb. 10, 2023 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTC-PINK: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, today announced that its common shares began trading on the OTC Markets Group's OTCPink Market in the United States under the symbol "TBPMF" effective at the opening of trading on Friday, February 10, 2023 and will continue to trade on the... Read More

Second Clarifax received from Health Canada. MONTREAL , Dec. 22, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with another regulatory update on the REDUVO™ New Drug Submission (NDS). The last update was provided on November 18, 2022 . On December 21, 2022 , the Company received a... Read More

The combination of ARDS-003 and Favipiravir presents viable treatments against viral infections. Results from the PIONEER clinical trial shows Favipiravir may improve severe COVID-19 recovery and ventilator-free survival in younger patients. Tetra and Cellvera to develop an orally administered treatment, ARDS-003, in combination with Favipiravir. MONTREAL , Dec. 6, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the... Read More

MONTREAL , Nov. 18, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with a regulatory status update on the REDUVO™ New Drug Submission (NDS). On December 30, 2020 , the Company submitted its first new drug submission ("NDS") for the REDUVO™ soft gel capsules to Health Canada to... Read More

Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that the Company has closed the second tranche of its previously announced financing arrangement (the " Financing ") with Global Corporate Finance Opportunities 16 (the " Investor "), an investment vehicle advised by Alpha Blue Ocean (" ABO "), pursuant to... Read More

Companies jointly submitted a $750,000 USD application to BARDA to use Prepaire™ Shield discovery platform to assess repurposed drugs combined with onternabez as Chemical Threat Medical Countermeasures. Partnership leverages respective expertise, technology, and capabilities to identify new combination therapies and improve clinical trajectories of patients exposed to pulmonary and nerve chemical agents. Tetra Bio-Pharma... Read More

Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that the Company has revised the terms of its previously announced financing arrangement (the " Financing ") with Global Corporate Finance Opportunities 16 (the " Investor "), an investment vehicle advised by Alpha Blue Ocean (" ABO "), and has closed the... Read More

Tetra and Cellvera to jointly develop an orally administered treatment, ARDS-003, in combination with the proven broad-spectrum antiviral, Qifenda 400MG (Favipiravir) Companies will jointly develop a combination therapeutic candidate for rapid clearance of COVID-19 infection The partnership aims to accelerate the global development of an innovative drug candidate to combat viral diseases by leveraging expertise and resources... Read More

Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that it has entered into a subscription agreement (the " Subscription Agreement ") with Global Corporate Finance Opportunities 16 (the " Investor "), an investment vehicle advised by Alpha Blue Ocean Inc. (" ABO "), whereby Tetra has agreed to issue to the... Read More

ARDS-003 is a novel therapeutic for acute systemic inflammation and prevention of acute respiratory distress syndrome (ARDS). ARDS-003 may offer steroid-sparing opportunities. ARDS-003 has demonstrated antiviral properties. ARDS-003 developed as an oral formulation for an immediate release administration. Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived... Read More

Provides Tetra with stable supply of high-quality ingredients and regulatory-approved services to satisfy clinical trials and prescription products Diversifies Akanda into cancer pain medical market as a specialized manufacturer of cannabis-based drugs for use in FDA clinical trials and pharmaceutical markets Akanda Corp.... Read More

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announces the launch of its new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd' ("TBP-AU"), an Australian-based research company focused on the execution of clinical trials in Australia . This represents Tetra's second foreign subsidiary and is in line with the... Read More

Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, held its annual general and special meeting (the " Meeting ") of its holders of common shares (the " Shareholders ") virtually on May 30, 2022 . The Company is pleased to announce that all matters presented for approval at the Meeting were approved, except with respect to... Read More

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and development is pleased to announce the appointment of Leslie Auld , H.BSc, MBA, CPA, as Chief Financial Officer and member of the Company's executive team, effective May 30, 2022 . Ms. Auld is a seasoned Financial Executive with over 30 years of relevant experience, including a background... Read More

Novel proprietary cannabidiol (CBD) therapeutic has been classified as an orphan medicinal product for the indication of epidermolysis bullosa (EB). Drug is ready for human clinical trials. Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced that the European Medicines Agency (EMA) has classified PPP004 as... Read More

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the closing of the first tranche of the previously announced private placement with Cannvalate Pty Ltd (" Cannvalate "), resulting in the issuance of 8,236,681 common shares in the capital of the Company (the " Common Shares "), representing 1.95% of the... Read More

Panag Pharma Inc (Panag), a subsidiary of Tetra Bio-Pharma, will collect royalties on sales on products produced with the technology True North has licensed from Panag. Use of a highly innovative proprietary liposome encapsulated technology leads to a better CBD absorption. This New True North Nectar product line in liquid and powder formats are expected to launch in select markets in Q4 2022. Tetra Bio-Pharma Inc. (" Tetra... Read More

Cannvalate to invest CAD$7.5M in Tetra. Cannvalate to launch and manage QIXLEEF™ and CAUMZ™ clinical trials in Australia . The Company to benefit from a 43.5% tax credit on all money spent on clinical trials in Australia . Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in... Read More

The Type C meeting with the FDA provides guidance to strengthen QIXLEEF™ nonclinical and toxicological data package for marketing approval. Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development received the response letter for a... Read More

Health Canada approved the amendment of the phase I study to assess the effect of low and moderate doses of inhaled CBD in healthy cannabinoid users. The collaboration with the CRCHUM will allow Tetra to obtain phase I clinical data on inhaled CBD. Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF)... Read More

Significant reduction in cash burn rate Preliminary data on QIXLEEF™ safety and efficacy Update on REDUVO™ New Drug Submission Update on ARDS-003 preclinical SARS-CoV-2 studies Disclosure of revised intangible assets Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in... Read More

Tetra Bio-Pharma Inc (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, today announced it has signed a Licensing Agreement with Thorne Health Tech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions... Read More

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development is proud to announce the approval of a $4.5M CDN participative loan from the ministère de l'Économie et de l'Innovation (MEI) under the BioMed Propulsion Program, managed by... Read More

The proposed partnership will encompass three potential strategic pillars across supply of API, commercialization of prescription products, and co-development of pharmaceutical drug candidates. Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery... Read More

Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the closing of its marketed public offering (the " Offering ") of 13,064,000 units of the Company (the " Units "), at a price of $0.163 per Unit for aggregate gross proceeds of $2.1 million . The Offering was co-led by Research Capital Corporation... Read More

Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the price of its marketed public offering (the “ Offering ”) of units of the Company (the “ Units ”) previously announced on December 1, 2021. Pursuant to the Offering, the Company intends to issue Units at a price of $0.163 per Unit for aggregate... Read More

EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets, announces the Schedule of the 21 st Emerging Growth Conference. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the... Read More

Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has entered into an agreement with Research Capital Corporation and Echelon Wealth Partners Inc., acting as co-lead agents and joint bookrunners (the " Agents "), in connection with a marketed public offering of units of the Company (the "... Read More

Tetra Bio-Pharma Confirms Meeting with the FDA to Align on the Requirements for Marketing Authorization Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced that it received a letter from the United States Food and... Read More

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced positive initial clinical data from its ongoing Phase 2 clinical trials (REBORN © 1 and PLENITUDE © ) of QIXLEEF™ for cancer pain. QIXLEEF™ is a botanical... Read More

Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, announced today the termination of its previously announced "at-the-market" equity offering program (the " ATM Program ") with Canaccord Genuity Corp. as sole agent. The... Read More

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the Company's application for Orphan Drug... Read More

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today provided an update on the progress and significant achievements of its lead investigational drug, QIXLEEF™. QIXLEEF™ is a botanical inhaled drug product with a fixed ratio... Read More

Tetra is gearing up to launch REDUVO™, its first cannabinoid-derived medicine, in Canada . REDUVO™ 5-year cumulative gross sales expected to reach $121M . The Company has started numerous pre - launch activities to prepare for the introduction of REDUVO™ on the Canadian Market. Tetra Bio-Pharma Inc. ("Tetra" or the "Company" )... Read More

SAA Report endorsed Tetra Bio-Pharma's proposed nonclinical development and quality programs for QIXLEEF™. SAA Report provides clarity on clinical requirements for registration in Europe . Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and... Read More

Tetra Bio-Pharma Inc ("Tetra" or the Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No. PCT/CA2021/050886, with a filing date of June 28, 2021 . Through the Tetra partnership with Thorne HealthTech, a submission to the U.S. Food and Drug... Read More

Important step for Tetra to ensure meaningful collaboration and patient engagement in research. Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today it has engaged Christine Caron as Patient Partner to support significant and active collaboration in research, knowledge translation, and patient engagement within... Read More

Ethics Committee approves REBORN1© protocol amendment allowing for the addition of two immediate release oral opioids to be compared against QIXLEEF™. REBORN1© is the first of its kind proof-of-concept phase 2 study comparing a cannabinoid-based drug, QIXLEEF™, to immediate release oral opioid for the treatment of breakthrough cancer pain. QIXLEEF™ has the potential to transform the pain market, offering an alternative to... Read More

Tetra Bio-Pharma Inc. ( " Tetra " or the " Company " ) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, announced today that Jean-François Boily has resigned as Chief Financial Officer of the Corporation effective July 16 th , 2021 to pursue another business opportunity. Tetra has commenced an executive search for a new Chief Financial Officer. The Company intends to use... Read More

Combining ARDS-003 with antiviral drugs significantly decreased viral replication compared to antiviral treatment alone. Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that its investigational new drug... Read More

This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 28, 2021 to its short form base shelf prospectus dated April 1, 2020 The Company approaches a significant milestone advancing from a pre-revenue biotech to in revenue Tetra Bio-Pharma Inc. ("Tetra" or the... Read More

Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that all matters presented for approval at the Company's annual general and special meeting (the " Meeting ") of shareholders of the Company held earlier today via live audio webcast online were approved. Election of Directors and Resolutions All of... Read More

First REBORN1© patient enters clinical trial. Positive results of first study in Sars-CoV-2 infected mice. Filing of IND for ARDS-003 Adaptive Phase 1a/ 1b clinical trial. Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development is pleased to announce that the first patient has entered the REBORN1© clinical trial; the first... Read More

Tetra Bio-Pharma Inc. (the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that, in connection with its previously announced bought-deal public offering (the " Offering ") of units (the " Units ") of the Company for aggregate gross proceeds to the Company of $10,000,000 , Echelon Wealth Partners Inc., as Lead Underwriter on behalf of a... Read More

Tetra Bio-Pharma Inc . (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, wishes to announce changes to its board of directors (the " Board ") and the filing of a supplement to its management information circular dated April 20, 2021 (the " Circular ") filed on SEDAR under the Company's profile at www.sedar.com . The Company wishes to announce... Read More

Tetra Bio-Pharma Inc. (the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce it has closed its previously announced bought-deal public offering of units (the " Units ") of the Company. A total of 25,000,000 Units of the Company were sold at a price of $0.40 per Unit, for aggregate gross proceeds to the Company of $10,000,000 (the "... Read More

Wall Street Reporter, the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor “LiveChats” on social media streams. Over 190,000 investors have participated in Wall Street Reporter’s livestream events in the past 30 days. Reliq Health Technologies (OTC: RQHTF)... Read More

First ever clinical trial using pharmaceutical grade cannabis medication for use in managing uncontrolled cancer pain due to advanced cancer QIXLEEF™ has the potential to transform the pain market Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery... Read More

Tetra Bio-Pharma Inc. (TSX: TBP) (OTCQB: TBPMF) (FSE:JAM1 ) (" Tetra " or the " Company ") is pleased to announce that it has entered into an agreement with a syndicate of underwriters led by Echelon Wealth Partners Inc. (the " Underwriters ") pursuant to which the Underwriters have agreed to purchase 25,000,000 units (the "... Read More

First ever Phase 2 clinical trial designed to evaluate the effect of cannabis against an opioid treatment QIXLEEF™ has the potential to transform the pain market Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development today announced... Read More

This Definitive Agreement is expected to generate an excess of $ 47,5M CAD in revenue for Tetra Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FSE:JAM1 ) , a leader in cannabinoid-derived drug discovery and development announced today the signing of a Definitive Agreement with DanCann Pharma A/S (SS:... Read More

The addressable market in Canada is estimated to be $80M CDN by 2022. Tetra also applies for a Health Canada Cannabis Drug License Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development today announced that the Company has been granted... Read More

Tetra plans for global commercialization of QIXLEEF Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today that it has submitted a request to the Malta Medicines Authority for a Scientific Opinion on its... Read More

First clinical study to assess cannabis as an alternative to morphine Tetra completes manufacturing of QIXLEEF clinical trial drug for REBORN1 trial Export permit received from Health Canada for immediate shipping to USA Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a leader in... Read More

Tetra strengthens its intellectual property portfolio Approximately 12% of women may have early symptoms of Interstitial Cystitis Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announces the granting of a new... Read More

REDUVO would have Canada's only Drug Identification Number for a THC-based prescription drug The addressable market is estimated to be $80M CDN by 2022 Tetra Bio-Pharma Inc . (" Tetra " or the " Company ") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce... Read More

FDA acknowledged that the preclinical safety data are acceptable to file an Investigational New Drug Application (IND) aimed at treating hospitalized COVID-19 patients at risk of developing ARDS Tetra Bio-Pharma Inc . (" Tetra " or the " Company ") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a biopharmaceutical pioneer in... Read More

Tetra Bio-Pharma Inc. receives a Notice of Compliant rated inspection to distribute pharmaceuticals Key milestone in the development path to commercialization of Reduvo Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and... Read More

Wall Street Reporter , the trusted name in financial news since 1843, is highlighting the latest CEO comments and news from companies recently presenting at its highly acclaimed NEXT SUPER STOCK livestream investor conferences, and investor “LiveChats” on social media streams. Over 170,000 investors have participated in Wall Street Reporter’s livestream events in the past 30 days. Tetra Bio-Pharma (OTC: TBPMF) (TSX: TBP)... Read More

Health Canada acknowledges that the preclinical safety data are robust and sufficient to file a Clinical Trial Application aimed at treating hospitalized COVID-19 patients at risk of developing ARDS ARDS is the leading cause of mortality in patients with COVID-19 and develops in 20-67% of critically ill patients diagnosed with... Read More

Tetra Bio-Pharma and Targeted Pharmaceuticals enter into an agreement to further its collaboration and co-development activities to advance Antiviral Central Nervous System Program The addressable global market for central nervous system drugs is expected to grow to $163.05 billion in 2025 Tetra Bio-Pharma Inc. ("Tetra" or the... Read More

Quantum Pharma Inc. is a contract facility operated by Tetra Bio-Pharma Inc Quantum Pharma Inc. receives a Notice of Compliant rated inspection Tetra Bio-Pharma Inc . (" Tetra " or the " Company ") (TSX:TBP) (OTCQB:TBPMF) (FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce that... Read More

Reduvo™ would be Canada's only DIN for a THC-based prescription drug The addressable market is estimated to be $80M CDN by 2022 Tetra Bio-Pharma Inc . (" Tetra " or the " Company ") (TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce that the Dronabinol Soft Gel... Read More

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development wishes to make the following correction to its news release dated February 25th, 2021. In the statement attributed to DanCann Pharma's CCO John Morell Frellsen, the estimate... Read More

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announces that CEO Dr. Guy Chamberland will present a company overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference being... Read More

Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development, is pleased to announce it has closed its previously announced bought-deal public offering of units (the " Units ") of the Company. A total of 65,550,000 Units of the Company (including the exercise in full of the over-allotment option granted to the Underwriters by the... Read More

Company signs LOI for Nordics and Germany Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced the signing of a Letter of Intent with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™ Adversa® and QIXLEEF™ in Denmark, Norway, Sweden, Finland, and Germany. Subject to registration with the... Read More

Tetra Bio-Pharma or the " Company " (TSX: TBP) (OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development, is pleased to announce that is has entered into an agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. (together, the " Underwriters ") pursuant to which the Underwriters have agreed to purchase, on a bought-deal basis, 45,500,000 units of the Company (the " Equity Units... Read More

Tetra Bio-Pharma Inc. (" Tetra Bio-Pharma " or the " Company ") (TSX: TBP) (OTCQB: TBPMF), a leader in cannabinoid-derived drug discovery and development announced today the closing of its previously announced non-brokered private placement (the " Offering ") of units of the Company (each, a " Unit "). A total of 11,085,064 Units were issued by the Company at a price of C$0.17 per Unit for aggregate gross proceeds of... Read More

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced today the creation of a wholly-owned subsidiary called ENJOUCA™. Jurisdictions differ greatly in terms of regulatory requirements surrounding medical cannabis, which means that in some territories, QIXLEEF™ can be commercialized as a medical cannabis product. As a... Read More

Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application, allowing Tetra to initiate its QIXLEEF TM Reborn1 TM clinical trial in cancer patients with breakthrough pain. "This is really good news for all of us and... Read More